Back to News
Market Impact: 0.35
Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer
Source: Bloomberg
Healthcare & Biotech
Doctors reported that combining medicines from Amgen and AstraZeneca helped patients with an aggressive form of lung cancer live eight months longer. The report does not specify the study size, treatment details, or regulatory implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
AMGN0.75
AZN0.75
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
- Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study
- Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Selecting an AI Research Platform for Institutional Investors
- Weekly Update: New Reporting Features and More Sources for Document Search